Citations

Clear

4510 citation(s) found for "Scott, C".

NCCN Guidelines® Insights: Survivorship, Version 2.2024
Sanft, Tara , Goldman, Mindy, Ansbaugh, Shannon, Fairman, Nathan, Feliciano, Josephine , Flores, Tessa , Gabel, Nicolette , Hill‐Kayser, Christine E. , Koura, Divya, McDonough, Allison L. , Melisko, Michelle , Mooney, Kathi , Moryl, Natalie , Neuman, Heather B. , Patel, Chirayu G. , Peterson, Lindsay L. , Porpiglia, Andrea S., Schapira, Lidia , Ah, Diane Von , Wake, Robert, Zee, Phyllis C. , McMillian, Nicole R., Freedman-Cass, Deborah A., Tevaarwerk, Amyé , Day, Andrew T. , Armenian, Saro H. , Baker, Kevin Scott , Ballinger, Tarah Jean , Demark‐Wahnefried, Wendy , Friedman, Debra L. , Lee, Kimberley T. , Lee, Nita Karnik , Moore, Halle C. F. , Overholser, Linda , Pirl, William F. , Schwartz, Anna L. , Smith, Sophia K. , Yang, Eric H. , Ah, Diane Von

Mayo Clinic

Journal of the National Comprehensive Cancer Network | December 16, 2024 | Volume: 22 | Issue: 10 | Pages: 648-658

10.6004/jnccn.2024.0062 | PMID 39689426 Get It

The NCCN Guidelines for Survivorship include recommendations for screening, evaluation, and treatment of psychosocial and physical problems resulting from adult-onset cancer and its treatment. They also include recommendations to promote healthy behaviors and immunizations in survivors and provide a framework for care coordination. These NCCN Guidelines Insights summarize the panel’s current recommendations regarding sexual health and fertility.
Supporting Patient Involvement in U.S. Medical Education Through Changes in Accreditation
Tackett, Sean , Steinert, Yvonne , Adams, Gayle Johnson, Reed, Darcy A. , Whitehead, Cynthia , Wright, Scott M. , Whitehead, Cynthia R , Wright, Scott M , Jackson, Jeffrey L.

Mayo Clinic

Teaching and Learning in Medicine | December 15, 2024 | Volume: 38 | Issue: 1 | Pages: 116-125

10.1080/10401334.2024.2439850 | PMID 39676226 Get It

Effect of Sacubitril/Valsartan in Heart Failure with Preserved Ejection Fraction Across the Age Spectrum in PARAGON-HF
Claggett, Brian, Chatur, Safia , O’Meara, Eileen , Rouleau, Jean L. , Redfield, Margaret M. , Lam, Carolyn, Packer, Milton, Shah, Amil M. , Čikeš, Maja , Pfeffer, Marc A., Solomon, Scott D. , Redfield, Margaret, Shah, Amil , Wang, Xiaowen , Vardeny, Orly , Claggett, Brian , Vaduganathan, Muthiah , Hegde, Sheila M. , Skali, Hicham , Pabón, Maria A. , Foà, Alberto , Kosztin, Annamária , Lam, Carolyn S.P. , Zile, Michael R. , Packer, Milton , Gori, Mauro , Merkely, Béla , McMurray, John J.V. , Solomon, Scott David

Mayo Clinic

European Journal of Heart Failure | December 15, 2024 | Volume: 27 | Issue: 1 | Pages: 96-106

10.1002/ejhf.3535 | PMID 39675788 Get It

Abstract Aims To evaluate clinical outcomes, echocardiographic features, and the efficacy and safety of sacubitril/valsartan compared to valsartan across age groups in the PARAGON-HF trial. Methods and results A total of 4796 participants ≥50 years of age with chronic heart failure (HF) and left ventricular ejection fraction (LVEF) ≥45% were divided into three age groups: <65 years (n = 825), 65–74 years (n = 1772), and ≥75 years (n = 2199). Echocardiograms of 1097 patients were analysed in a standardized fashion at a core imaging laboratory. The primary composite outcome was total HF hospitalizations and cardiovascular (CV) death. Older patients were more likely to experience primary composite outcomes (compared to patients <65 years, adjusted rate ratio [aRR] for ≥75 years: 1.39, 95% confidence interval [CI] 1.21–1.61), total HF hospitalization (aRR 1.27, 95% CI 1.09–1.49), and CV death (adjusted hazard ratio [aHR] 2.04, 95% CI 1.44–2.87). Age did not modify the effect of sacubitril/valsartan compared to valsartan on primary composite endpoint (pinteraction = 0.79) in the overall population or in those with LVEF ≤57%. Older adults randomized to sacubitril/valsartan were more likely to develop hypotension compared to those receiving valsartan (pinteraction = 0.026). Older patients had smaller left ventricular chamber sizes, higher LVEF, and were more likely to have abnormal measures of diastolic function. Conclusion Older patients with HF with preserved ejection fraction had higher event rates than younger patients, more adverse events overall, and more hypotension when treated with sacubitril/valsartan; however, the treatment benefits of sacubitril/valsartan were retained in older patients.
SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers
Shroff, Rachna T. , King, Gentry Teng , Colby, Sarah, Scott, Aaron J. , Borad, Mitesh J. , Goff, Laura W. , Matin, Khalid , Mahipal, Amit , Kalyan, Aparna, Javle, Milind , Dika, Imane El , Tan, Benjamin , Cheema, P. , Iyer, Renuka , Kelley, Robin Kate , Thumar, Jaykumar , Guthrie, Katherine A. , Chiorean, E. Gabriela , Höchster, Howard S. , King, Gentry , Javle, Milind M , Cheema, Puneet S , Patel, Anuj , Iyer, Renuka , Kelley, R Katie , Thumar, Jaykumar , El-Khouiery, Anthony B , Chiorean, E Gabriela , Hochster, Howard , Philip, Philip , Mahipal, Amit , Borad, Mitesh J , Patel, Anuj , El-Khoueiry, Anthony B. , Philip, Philip A.

Mayo Clinic

Journal of Clinical Oncology | December 13, 2024 | Volume: 43 | Issue: 5 | Pages: 536-544

10.1200/jco-24-01383 | PMID 39671534 Get It

PURPOSE SWOG S1815 was a randomized, open label phase III trial, evaluating gemcitabine, nab-paclitaxel, and cisplatin (GAP) versus gemcitabine and cisplatin (GC) in patients with newly diagnosed advanced biliary tract cancers (BTCs). METHODS Patients with newly diagnosed locally advanced unresectable or metastatic BTC, including intrahepatic cholangiocarcinoma (ICC) and extrahepatic cholangiocarcinoma (ECC) and gallbladder carcinoma (GBC), were randomly assigned 2:1 to either GAP (gemcitabine 800 mg/m 2 , cisplatin 25 mg/m 2 , and nab-paclitaxel 100 mg/m 2 intravenously once per day on days 1 and 8 of a 21-day cycle) or GC (gemcitabine 1,000 mg/m 2 and cisplatin 25 mg/m 2 intravenously once per day on days 1 and 8 of a 21-day cycle). RESULTS Among 452 randomly assigned participants, 441 were eligible and analyzable, 67% with ICC, 16% with GBC, and 17% with ECC. There was no significant difference in overall survival (OS) between GAP versus GC. Median OS with GAP was 14.0 months (95% CI, 12.4 to 16.1) and 13.6 months with GC (95% CI, 9.7 to 16.6); hazard ratio (HR), 0.91 (95% CI, 0.72 to 1.14); P = .41. Median progression-free survival (PFS) was similar between groups with median PFS for GAP being 7.5 months (95% CI, 6.4 to 8.5) versus 6.3 months for GC (95% CI, 4.4 to 8.2); HR, 0.89 (95% CI, 0.71 to 1.12); P = .32. In exploratory subset analyses, the OS and PFS benefits of GAP versus GC treatment were greater in locally advanced disease compared with metastatic disease, although not statistically significant (interaction P = .14 for OS and P = .17 for PFS). Moreover, GAP versus GC showed greater improvement in PFS among participants with GBC than those with ICC or ECC (interaction P = .01), but not OS (interaction P = .28). CONCLUSION The addition of a taxane in the GAP regimen to the standard gemcitabine-cisplatin regimen did not improve OS in newly diagnosed BTC. More toxicity was encountered with GAP versus GC.
Pharmacogenetic and microRNA mechanisms of beta blocker use on bone
Lary, Christine W. , Atkinson, Elizabeth J. , Nayema, Zannatun, Roy, Tyler, Peters, Rebecca , Scott, Griffin T, Chen, Hongyu , Nagarajan, Archana , Brown, Aaron, Motyl, Katherine J. , Monroe, David G , Spillane, Jennifer, Scott, Griffin T, Brown, Aaron, Monroe, David G. , Khosla, Sundeep

Mayo Clinic

Journal of Bone and Mineral Research | December 13, 2024 | Volume: 40 | Issue: 2 | Pages: 231-240

10.1093/jbmr/zjae200 | PMID 39673185 Get It

Abstract Motivated by studies showing an association between beta blocker (BB) use and positive bone outcomes, a pilot randomized control trial was performed at the Mayo Clinic which randomized postmenopausal women to placebo, propranolol (40 or 80 mg twice daily), atenolol (50 mg/d), or nebivolol (5 mg/d) to determine changes in bone turnover markers (BTMs) and in BMD over 20 wk. Pharmacogenetic effects and microRNA-mediated mechanisms involving beta adrenergic receptor and related genes have previously been found. We sought to validate these effects and discover new candidates in an ancillary study to the pilot clinical trial. We genotyped all participants and performed microRNA (miRNA) sequencing at baseline and at 20 wk for 24 participants from the atenolol or placebo groups. We discovered several variants in ADRB1, ADRB2, and HDAC4 which showed significant pharmacogenetic effects with BMD at multiple sites and with BTMs. Our miRNA results showed a significant treatment effect for miR-19a-3p over time with atenolol use in the low-responder group compared to placebo. Overall, the longitudinal miRNA analysis showed a large number of miRNAs which were up-regulated over the trial in the low responders but not the high responders compared to placebo, of which miR-19a-3p was one example. Finally, we compared the response to atenolol treatment for cardiovascular traits (pulse and blood pressure) with the response for the bone resorption marker, C-terminal telopeptide, and found a largely independent effect. Our results have implications for personalized therapy and for understanding mechanisms of BB treatment effect on bone.
Management of Acute Decompensated Valvular Heart Disease
Lüsebrink, Enzo , Lanz, Hugo, Kellnar, Antonia , Karam, Nicole , Makkar, Raj, Abraham, William T. , Leon, Martin B. , Sannino, Anna , Shuvy, Mony , Guerrero, Mayra , Fam, Neil , Butler, Javed, Adamo, Marianna, Rudolph, Volker , Tang, Gilbert , Rommel, Karl-Philipp , Thiele, Holger , Maßberg, Steffen , Prendergast, Bernard, Hausleiter, Jörg , Hausleiter, Jörg , Sannino, Anna , Kapadia, Samir , Makkar, Raj , Latib, Azeem , Guerrero, Mayra , Adamo, Marianna , Stocker, Thomas J. , Lurz, Philipp , Praz, Fabien

Mayo Clinic

European Journal of Heart Failure | December 12, 2024 | Volume: 27 | Issue: 4 | Pages: 630-649

10.1002/ejhf.3549 | PMID 39663714 Get It

Abstract Worldwide, valvular heart disease (VHD) is a common cause of hospitalization for acute heart failure. In acute heart failure caused by VHD, symptoms result from rapid haemodynamic changes and subsequent decline in cardiac function, and if left untreated, leads to acute decompensation and cardiogenic shock. Current evidence remains scarce and recommendations regarding the management of acute heart failure caused by VHD are lacking in most recent international guidelines. Herein, we review the management of acute heart failure caused by VHD with a focus on transcatheter therapies and describe currently available evidence based on a systematic literature search on the following valve pathologies: (i) aortic stenosis, (ii) aortic regurgitation, (iii) mitral regurgitation, and (iv) mitral stenosis. Articles reporting outcomes following urgent or emergent valve intervention in the setting of cardiogenic shock or acute heart failure were considered. After screening a total of 2234 articles, 76 published between 1994 and 2023 were included in subsequent analysis. Based on available evidence, proposed treatment algorithms to guide optimal management of acute heart failure caused by VHD were created. As the number of patients presenting with acute heart failure caused by VHD continues to rise and outcomes following transcatheter valve interventions continue to improve, it is inevitable that minimally invasive options will play an increasingly important role in the acute setting, especially given these patients are at an increased operative risk. This review aims to present an organized approach to the complex management and interventional treatment of patients with acute heart failure caused by VHD.
Primary retroperitoneal lymph node dissection in clinical stage 2a/b non‐seminomatous germ cell tumour
Antonelli, Luca , Heidenreich, Axel , Baky, Fady , Branger, Nicolas , Daneshmand, Siamak , Djaladat, Hooman , Eggener, Scott E. , Sexton, Wade J. , Nicol, David , Olson, Kathleen, Paffenholz, Pia , Porter, James , Qian, Zhiyu , Rocco, Nicholas R., Stroup, Sean P. , Tachibana, Isamu , Cary, Clint , Daneshmand, Siamak , Djaladat, Hooman , Ghoreifi, Alireza , Nicol, David , Nicolai, Nicola , Paffenholz, Pia , Porter, James , Stroup, Sean P , Fankhauser, Christian Daniel , Bagrodia, Aditya , Amini, Armon , Cazzaniga, Walter , Clinton, Timothy Nguyen , Ghoreifi, Alireza , Hamilton, Robert J , Ho, Matthew, Nazzani, Sebastiano , Olson, Kathleen, Yerrapragada, Anirudh , Terbuch, Angelika , Singla, Nirmish

Mayo Clinic

BJU International | December 11, 2024 | Volume: 135 | Issue: 4 | Pages: 621-628

10.1111/bju.16618 | PMID 39662898 Get It

Objectives To reassess the role of primary retroperitoneal lymph node dissection (RPLND) in patients with marker‐negative non‐seminomatous germ cell tumour (NSGCT) clinical stage (CS) 2a, to explore results in patients with CS 2b and to evaluate surgical methods, recurrence, and adjuvant chemotherapy indications. Materials and Methods Data from 17 institutions were collected, comprising 305 men who underwent primary RPLND for CS 2 NSGCT. Regression analyses were conducted to predict histology in the RPLND specimen and disease‐free survival (DFS). Results A larger retroperitoneal lymph node diameter was associated with pure teratoma in the RPLND specimen (odds ratio [OR] 1.02, 95% confidence interval [CI] 1.01–1.07; P = 0.03), but no association was observed with DFS. The 5‐year DFS rates in marker negative CS 2a and 2b were 79% and 76%. In men with non‐teratomatous viable cancer in the RPLND specimen, the 5‐year DFS rates for CS 2a and 2b were 95% and 87% with adjuvant chemotherapy, and 67% and 74% without adjuvant chemotherapy. We did not identify an association between the number of adjuvant chemotherapy cycles and DFS. Conclusions Our study suggests considering primary RPLND not only in marker‐negative CS 2a but also in CS 2b. Further research should determine the efficacy of primary RPLND in men with CS 2c and marker‐positive CS 2, as well as which patients may benefit from adjuvant chemotherapy and the optimal cycle number.
(234) USING PERCUTANEOUS ULTRASOUND-GUIDED THROMBIN INJECTION AS A TREATMENT OF HIGH-FLOW PRIAPISM
Colquitt, John L. , Naidu, Sailendra , Colquitt, J, Warren, C, Young, Scott W. , Punjani, Nahid

Mayo Clinic

The Journal of Sexual Medicine | December 11, 2024 | Volume: 21 | Issue: Supplement_7 | Pages: No page available

10.1093/jsxmed/qdae167.228 Get It

Abstract Introduction Nonischemic priapism typically occurs secondary to penile trauma, resulting in increased blood flow into the penis without decreased outflow resulting in a clinically non-painful, partially rigid erection. Per the American Urologic Association guidelines, surgical treatment is discouraged, and following conservative management, first line treatment is arteriography with selective arterial embolization. This procedure is generally highly successful but it does carry a risk of erectile dysfunction as well as priapism recurrence. Objective Herein we present the first known case of ultrasound guided thrombin injection in an adult for nonischemic priapism treatment after persistent priapism and arterial blush following arterial embolization. Methods A 44-year-old male presented with an eight-month history of partial tumescence and erectile dysfunction after an episode of unwitnessed loss of consciousness resulting in the subsequent development of gross hematuria and dysuria. Physical examination revealed a semi-firm penis with suspected high-flow priapism. He initially presented to the emergency department, whereby a cystogram and cross sectional abdominal imaging were unrevealing. Initial outpatient cystoscopy revealed a urethral polyp which resolved on subsequent repeat testing. Following this an outpatient penile duplex doppler ultrasound was performed demonstrating a right pseudoaneurysm at the penile base measuring 13 mm in diameter with an arteriovenous fistulous communication to the corpus cavernosum. MRI demonstrates fibrotic changes within the right corpus cavernosum and tunica albuginea indicating prior traumatic penile injury. At the time the patient had approximately 25% tumescence at rest and was only able to obtain a slightly firmer erection, but was still able to achieve orgasm. After extensive conversation and given a trial of conservative management, the patient elected to proceed with angioembolization. An angiogram was completed which demonstrated a blush of contrast in the area of the bulbourethral artery. Despite successful deployment and coil embolization of the pseudoaneurysm, there was noted continued filling of the patent pseudoaneurysm from small branched collateral vessels. The patient tolerated the procedure well, and had reduction of his baseline penile tumescence and some erectile function recovery, requiring oral phosphodiesterase-5 inhibitors. There was concern for complete occlusion of the dorsal penile artery with repeat embolization, which may ultimately worsen erectile dysfunction. He remained incompletely satisfied with response to oral therapy. Results It was ultimately decided to pursue an ultrasound guided thrombin injection, which has been reported in a handful of cases as a primary intervention for priapism. During the procedure, 200 units of thrombin was injected into the pseudoaneurysm under ultrasound guidance resulting in immediate cessation of arterial flow. Post-procedure angiography demonstrated effective resolution. Conclusions High-flow priapism is a relatively uncommon condition, managed generally with embolization as first line treatment, with success rates reported at 89 to 100% and recurrence only occurring in 30% of patients. Recurrence is generally treated with repeat embolization which has been reported to cause erectile dysfunction in 15 to 22% of cases. Percutaneous ultrasound-guided thrombin injection has the potential to be an excellent second-line treatment option for pseudoaneurysm closure in correcting nonischemic priapism, albeit with limited data, but suspected high efficacy and potentially diminished rates of erectile dysfunction. Disclosure No.
Association between Locoregional Failure and NFE2L2/KEAP1/CUL3 Mutations in NRG/RTOG 9512: A Randomized Trial of Radiation Fractionation in T2N0 Glottic Cancer
Guan, Li , Torres‐Saavedra, Pedro A. , Zhao, Xiaobei , Major, Michael B. , Holmes, Brittany , Nguyen, Ngan K. , Kumaravelu, Parasakthy , Hodge, Tim , Diehn, Maximilian , Zevallos, Jose P. , Emami, Bahman, Hayward, Michele C. , Sagar, Stephen M. , Morrison, William H. , Schultz, Christopher J. , Jones, Christopher U. , Galloway, Thomas J. , Yom, Sue S. , Kudrimoti, Mahesh , Kim, Harold E., Harris, Jonathan , Le, Quynh‐Thu , Holmes, Brittany J , Zevallos, Jose , Holsinger, F Chris , Emami, Bahman , Jordan, Richard C , Hayward, Michele C , Sagar, Stephen M , Morrison, William , Schultz, Christopher , Caudell, Jimmy J , Jones, Christopher U , Bratman, Scott V , Galloway, Thomas J , Ma, Daniel , Yom, Sue S , Kudrimoti, Mahesh , Kim, Harold E , Harris, Jonathan , Le, Quynh-Thu , Hayes, D Neil , Diehn, Maximillian , Holsinger, F. Christopher , Daniel, J.

Mayo Clinic

Clinical Cancer Research | December 10, 2024 | Volume: 31 | Issue: 9 | Pages: 1615-1624

10.1158/1078-0432.ccr-24-2334 | PMID 39656603 Get It

Abstract Purpose: NFE2L2/KEAP1/CUL3 mutations have been validated for radioresistance in cell-based assays and animal models. However, clinical validation of these biomarkers has been challenging because of multimodality treatment regimens. This study aims to investigate the association between NFE2L2/KEAP1/CUL3 mutations and patient outcomes, including local failure, locoregional failure, disease-free survival (DFS), and overall survival, using samples from a phase III trial in which patients were treated with radiation monotherapy at two controlled doses. Patients and Methods: We investigated NFE2L2/KEAP1/CUL3 mutations in 250 randomized patients with T2N0 glottic squamous cell carcinoma receiving definitive radiotherapy in the NRG/RTOG 9512 trial. A total of 119 patients had available biospecimens that were subjected to amplicon-based next-generation sequencing to assess for the presence of NFE2L2/KEAP1/CUL3 mutations without regard to outcomes. Mutations in NFE2L2/KEAP1/CUL3 were assessed blinded to clinical outcomes. Cox models (two-sided α = 0.05) were used to evaluate the association with clinical outcomes, performed by an independent statistical team. Results: Nineteen of 119 patients (16.0%) had NFE2L2/KEAP1/CUL3 mutations. Patient, treatment, and tumor characteristics were similar between those with and without mutations. Patients with mutation compared with those without had significantly more local failure [HR = 3.50; 95% confidence interval (CI), 1.56–7.89; P = 0.0025] and locoregional failure (HR = 3.80; 95% CI, 1.80–8.03; P = 0.0005). DFS was significantly worse for the mutated compared with the nonmutated group in the first 2 years (HR = 2.88; 95% CI, 1.46–5.66; P = 0.0022). The median DFS was shorter in the mutation group (10.3 months) versus those with intact NFE2L2/KEAP1/CUL3 (4.2 years). Conclusions: NFE2L2/KEAP1/CUL3 mutations may predict radiation treatment failure in T2N0 glottic cancer. See related commentary by Rao, p. 1563
Digital Technologies Tracking Active and Passive Data Collection in Depressive Disorders: Lessons Learned From a Case Series
Gardea‐Resendez, Manuel , Breitinger, Scott , Harper, Laura , Stoppel, Cynthia , Volety, Rama , Raman, Jeyakumar, Byun, Jin Soo, Langholm, Carsten , Zandi, Peter P. , Frye, Mark A. , Xiong, Ashley , Volety, Rama M, Gardea-Resendez, Manuel , Walker, Alex, Raman, Jeyakumar, Goes, Fernando , Torous, John Blake

Mayo Clinic

Journal of Psychiatric Practice | December 10, 2024 | Volume: 30 | Issue: 6 | Pages: 434-439

10.1097/pra.0000000000000820 | PMID 39655971 Get It

In this case series, we present several examples from participants (2 patients and 1 healthy control) of a 12-week pilot feasibility study to create a digital phenotype of depression (unipolar or bipolar) through active and passive data collection from a smartphone and a wearable device combined with routine clinical care for mood disorders. The selected cases represent real clinical examples that highlight the intrinsic challenges that should be expected when conducting similar studies, including appropriate health data privacy protection, clinical standardization, and interindividual differences in levels of engagement and acceptability of active and passive data collection (ie, self-reported, behavioral, cognitive, and physiological data), particularly with patient-generated data in mobile apps, digital proficiency habituation, and consistent use of wearable devices. In the context of the rapidly growing use of digital technologies in psychiatry, anticipating challenges for the integration of personal mobile devices and smartphone mental health apps as aides to track specific aspects of depressive disorders is critical for a clinically meaningful digital transformation of mood disorders care.